{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166105002",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166105002",
  "name" : "CPIC Dosing Guideline for desipramine and CYP2D6",
  "relatedDrugs" : [ {
    "objCls" : "Drug",
    "@id" : "https://www.pharmgkb.org/data/drug/PA449233",
    "@context" : "https://www.pharmgkb.org/jsonld/drug.jsonld",
    "id" : "PA449233",
    "name" : "desipramine"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA128",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA128",
    "symbol" : "CYP2D6",
    "name" : "cytochrome P450, family 2, subfamily D, polypeptide 6"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>Tricyclic antidepressants have comparable pharmacokinetic properties, it may be reasonable to apply the CPIC Dosing Guideline for amitriptyline/nortriptyline and CYP2C19, CYP2D6 to other tricyclics including desipramine. In the guideline for nortriptyline, an alternative drug is recommended for CYP2D6 ultrarapid metabolizers or poor metabolizers. For intermediate metabolizers, a 25% dose reduction may be considered.</p>",
  "textHtml" : "<p>Guidelines regarding the use of pharmacogenomic tests in dosing for tricyclic antidepressants have been published in Clinical Pharmacology and Therapeutics by the <a href=\"/contributors/consortia/cpic_profile.jsp\">Clinical Pharmacogenetics Implementation Consortium (CPIC)</a>.</p><p><strong>Download:</strong> <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_TCAguideline2012.pdf\">article</a> and <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_TCAsupplement2012.pdf\">supplement</a></p><h5 id=\"Excerptfromthedosingguidelines\">Excerpt from the dosing guidelines:</h5><p>Amitriptyline and <a href=\"http://www.pharmgkb.org/drug/PA450657\">nortriptyline</a> are used as model drugs for this guideline because the majority of pharmacogenomic studies have focused on these two drugs. Because the tricyclics have comparable pharmacokinetic properties, it may be reasonable to apply this <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_TCAguideline2012.pdf\">guideline</a> to other tricyclics including desipramine (<a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_TCAsupplement2012.pdf\">Supplementary Table S15</a>), with the acknowledgement that there are fewer data supporting dose adjustments for these drugs than for amitriptyline or nortriptyline.<br/><br/>See <a href=\"http://www.pharmgkb.org/drug/PA450657\">nortriptyline</a> for excerpts and a table that summarize <em>CYP2D6</em>-based dosing recommendations for nortriptyline when higher initial starting doses are warranted (<a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_TCAguideline2012.pdf\">article</a>).</p>"
}